423 related articles for article (PubMed ID: 33173161)
1. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.
D'Alessio A; Del Poggio P; Bracchi F; Cesana G; Sertori N; Di Mauro D; Fargnoli A; Motta M; Giussani C; Moro P; Vitale G; Giacomini M; Borra G
Leukemia; 2021 Feb; 35(2):635-638. PubMed ID: 33173161
[No Abstract] [Full Text] [Related]
2. Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids.
Sarmiento M; Rojas P; Jerez J; Bertín P; Campbell J; García MJ; Pereira J; Triantafilo N; Ocqueteau M
Acta Haematol; 2021; 144(6):620-626. PubMed ID: 34111867
[TBL] [Abstract][Full Text] [Related]
3. Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer.
Portsmore S; Tran Nguyen TN; Beacham E; Neelakantan P
Br J Haematol; 2020 Aug; 190(4):525-528. PubMed ID: 32584421
[No Abstract] [Full Text] [Related]
4. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.
Gaspari V; Zengarini C; Greco S; Vangeli V; Mastroianni A
Int J Antimicrob Agents; 2020 Aug; 56(2):106023. PubMed ID: 32450201
[No Abstract] [Full Text] [Related]
5. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
Innes AJ; Cook LB; Marks S; Bataillard E; Crossette-Thambiah C; Sivasubramaniam G; Apperley J; Milojkovic D
Br J Haematol; 2020 Aug; 190(4):e198-e200. PubMed ID: 32593183
[No Abstract] [Full Text] [Related]
6. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.
Mortara A; Mazzetti S; Margonato D; Delfino P; Bersano C; Catagnano F; Lauriola M; Grosso P; Perseghin G; Ippoliti G
Clin Transl Sci; 2021 May; 14(3):1062-1068. PubMed ID: 33403775
[TBL] [Abstract][Full Text] [Related]
7. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.
Foss FM; Rubinowitz A; Landry ML; Isufi I; Gowda L; Seropian S; Perreault S; Shenoi SV
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):720-723. PubMed ID: 32727701
[TBL] [Abstract][Full Text] [Related]
8. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
9. Successfully treated severe COVID-19 and invasive aspergillosis in early hematopoietic cell transplantation setting.
Spadea M; Carraro F; Saglio F; Vassallo E; Pessolano R; Berger M; Scolfaro C; Grassitelli S; Fagioli F
Transpl Infect Dis; 2021 Apr; 23(2):e13470. PubMed ID: 32959932
[No Abstract] [Full Text] [Related]
10. [Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT)].
Mareev VY; Orlova YA; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Plisyk AG; Seredenina EM; Potapenko AV; Malakhov PS; Samokhodskaya LM; Mershina ЕА; Sinitsyn VE; Asratyan DA; Zhdanova EA; Mareev YV; Begrambekova YL; Shatochina EA; Kamalov АА
Kardiologiia; 2020 Oct; 60(9):4-21. PubMed ID: 33131470
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting.
Ovilla-Martinez R; Cota-Rangel X; De La Peña-Celaya J; Alvarado-Zepeda MA; Jiménez Sastré A; Azuara Forcelledo H; Ordoñez Rodriguez B; Pulido Broca J; Molina Jaimes A; Muñiz-Carvajal A; Bahena García MM; Cervera Ceballos E; Zapata Canto NP; García Mendez JO; García Jímenez ON; Salas Heredia JA; Solis Soto J; Villalobos Mendez RA; Ignacio Ibarra G; Ledesma de la Cruz C; Araujo Martinez N; Juárez Lara J; Ceballos Zuñiga CO; Villaseñor Pérez FV; Herrera Garcia JC; Nuche Salazar P; Dominguez Paregrina A; Arizpe Bravo B; Enciso Figueroa G; Trujillo T; Miguel Álvarez A; García Gallegos DJ; Ortiz Arroyo A; Solorzano Soto CI; Jaramillo Ramírez HJ; De la Cruz Hernández I; De Gante Martínez S; Montesinos Gómez GE; Martínez Velasco S; García Graullera R; Vázquez López MA; Urbalejo Ceniceros VI; Lugo García Y; González Ávila AI; Duque Rodriguez J; Ruiz Luján R; Rodríguez Rivera VI; Soberanes Ramírez L; Baez-Islas PE
J Infect Dev Ctries; 2022 Jan; 16(1):63-72. PubMed ID: 35192523
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib.
Caradec E; Mouren D; Zrounba M; Azoulay LD; Blandin C; Ivanoff S; Levy V; Brillet PY; Nunes H; Uzunhan Y
Respir Med Res; 2021 May; 79():100799. PubMed ID: 33242734
[No Abstract] [Full Text] [Related]
13. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.
Rojas P; Sarmiento M
Acta Haematol; 2021; 144(3):314-318. PubMed ID: 32726783
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib for Therapy of Graft-versus-Host Disease.
Neumann T; Schneidewind L; Weigel M; Plis A; Vaizian R; Schmidt CA; Krüger W
Biomed Res Int; 2019; 2019():8163780. PubMed ID: 30956985
[TBL] [Abstract][Full Text] [Related]
15. The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Neubauer A; Johow J; Mack E; Burchert A; Meyn D; Kadlubiec A; Torje I; Wulf H; Vogelmeier CF; Hoyer J; Skevaki C; Muellenbach RM; Keller C; Schade-Brittinger C; Rolfes C; Wiesmann T
Leukemia; 2021 Oct; 35(10):2917-2923. PubMed ID: 34385593
[TBL] [Abstract][Full Text] [Related]
16. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Barbui T; Vannucchi AM; Alvarez-Larran A; Iurlo A; Masciulli A; Carobbio A; Ghirardi A; Ferrari A; Rossi G; Elli E; Andrade-Campos MM; Kabat MG; Kiladjian JJ; Palandri F; Benevolo G; Garcia-Gutierrez V; Fox ML; Foncillas MA; Morcillo CM; Rumi E; Osorio S; Papadopoulos P; Bonifacio M; Cervantes KSQ; Serrano MS; Carreno-Tarragona G; Sobas MA; Lunghi F; Patriarca A; Elorza BN; Angona A; Mazo EM; Koschmieder S; Ruggeri M; Cuevas B; Hernandez-Boluda JC; Abadia EL; Cirici BX; Guglielmelli P; Garrote M; Cattaneo D; Daffini R; Cavalca F; Bellosillo B; Benajiba L; Curto-Garcia N; Bellini M; Betti S; De Stefano V; Harrison C; Rambaldi A
Leukemia; 2021 Feb; 35(2):485-493. PubMed ID: 33414483
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study.
Stanevich OV; Fomina DS; Bakulin IG; Galeev SI; Bakin EA; Belash VA; Kulikov AN; Lebedeva AA; Lioznov DA; Polushin YS; Shlyk IV; Vorobyev EA; Vorobyeva SV; Surovceva TV; Bakulina NV; Lysenko MA; Moiseev IS
BMC Infect Dis; 2021 Dec; 21(1):1277. PubMed ID: 34937556
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?
Guisado Hernández P; Blanco Lobo P; Villaoslada I; de Felipe B; Lucena JM; Martín Gutierrez G; Castro MJ; Gutiérrez Valencia A; Sánchez Codez MI; Gaboli M; Neth O; Olbrich P
J Clin Immunol; 2021 Oct; 41(7):1502-1506. PubMed ID: 34109505
[No Abstract] [Full Text] [Related]
19. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
20. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
Koschmieder S; Jost E; Cornelissen C; Müller T; Schulze-Hagen M; Bickenbach J; Marx G; Kleines M; Marx N; Brümmendorf TH; Dreher M
Eur J Haematol; 2020 Nov; 105(5):655-658. PubMed ID: 32593209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
